• Publications
  • Influence
The Influence of Cosolvents on the In‐vitro Percutaneous Penetration of Diclofenac Sodium From a Gel System
Abstract— The influence of cosolvents on the in‐vitro percutaneous penetration of diclofenac sodium from a gel system was studied using a simplex lattice experimental design. Gel formulations wereExpand
  • 62
  • 3
Novel cytokine release inhibitors. Part I: Triterpenes.
Tripterine and closely related triterpenoid derivatives as IL-1 beta release inhibitors are discussed.
  • 37
  • 1
RHC 3024: antiallergic activity in vitro and comparison with disodium cromoglycate and other antiallergic agents.
RHC 3024 has been investigated for its antiallergic activity in three in vitro models of anaphylaxis. We have also compared its activity profile in these models with that of disodium cromoglycateExpand
  • 7
Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and
The synthesis of a series of novel substituted hydroxamates has been described along with their profile of inhibitory activity against 5-lipoxygenase, 12-lipoxygenase, and cyclooxygenase enzymes. TheExpand
  • 31
Letter: Preparation of (R)- and (S)-mevalonic acids.
  • F. Huang, L. Lee, +5 authors C. Eck
  • Chemistry, Medicine
  • Journal of the American Chemical Society
  • 9 July 1975
  • 102
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
The synthesis and biological activity of a novel series of 2, 2-disubstituted indan-1,3-dione-based PDE4 inhibitors are described. This structurally unique class of PDE4 inhibitors is markedlyExpand
  • 21
Synthesis of 2-(2,3-dihydro-2-oxo-1,3,4-oxadiazol-5-yl) benzo heterocycles. A novel series of orally active antiallergic agents.
A series of new 2-(2,3-dihydro-2-oxo-1,3,4-oxadiazol-5-yl) benzo heterocycles has been prepared. These compounds were tested as inhibitors of antigen-induced release of histamine (AIR) in vitro fromExpand
  • 56
Orally active indole N-oxide PDE4 inhibitors.
This communication describes the synthesis and in vitro and in vivo evaluation of a novel potent series of phosphodiesterase type (IV) (PDE4) inhibitors. Several of the compounds presented possessExpand
  • 17
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
This communication describes the synthesis and in vitro evaluation of a novel potent series of phosphodiesterase type (IV) (PDE4) inhibitors. The compounds described contain an indole moiety whichExpand
  • 18